Stock Analiz

Acadia Pharmaceuticals Inc. (ACAD) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Acadia Pharmaceuticals’s revenue went from $17M in fiscal 2016 to $1.1B in fiscal 2025, growth of about 58.1% a year.

Net income in fiscal 2025 was $391M, a net margin of 36.5%; the highest of the period.

Over the twelve months to September 30, 2026, revenue was $1.2B and net income $362M.

Free cash flow was $105M in fiscal 2025 and positive in 3 of the 10 years shown.

The diluted share count fell 100% over the period (buybacks).

Revenue, profit and cash flow by year

Revenue
2016: $17M162017: $125M172018: $224M182019: $339M192020: $442M202021: $484M212022: $517M222023: $726M232024: $958M242025: $1.1B25$1.1B
Net income
2016: -$271M162017: -$289M172018: -$245M182019: -$235M192020: -$282M202021: -$168M212022: -$216M222023: -$61M232024: $226M242025: $391M25$391M
Free cash flow
2016: -$210M162017: -$219M172018: -$170M182019: -$152M192020: -$144M202021: -$127M212022: -$114M222023: $17M232024: $157M242025: $105M25$105M
EPS (diluted)
2016: $-0.00162017: $-0.00172018: $-0.00182019: $-0.00192020: $-0.00202021: $-0.00212022: $-1.34222023: $-0.37232024: $1.36242025: $2.3025$2.30

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$1.2B$1.1B$958M$726M$517M$484M$442M$339M$224M$125M$17M
Gross profit$1.1B$983M$876M$685M$507M$473M$432M$328M$211M$116M$14M
Operating income$122M$105M$231M-$73M-$224M-$170M-$287M-$247M-$247M-$292M-$273M
Net income$362M$391M$226M-$61M-$216M-$168M-$282M-$235M-$245M-$289M-$271M
EPS (diluted)$2.12$2.30$1.36$-0.37$-1.34$-0.00$-0.00$-0.00$-0.00$-0.00$-0.00
R&D$319M$329M$303M$352M$362M$239M$319M$240M$187M$149M$99M
Revenue growth—+11.9%+31.9%+40.5%+6.8%+9.6%+30.3%+51.5%+79.2%+620.7%+28311.5%

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow$98M$110M$158M$17M-$114M-$126M-$136M-$151M-$167M-$218M-$208M
Capital spending-$16M-$5M-$523000-$50000$0-$1M-$8M-$1M-$2M-$812000-$2M
Free cash flow$82M$105M$157M$17M-$114M-$127M-$144M-$152M-$170M-$219M-$210M
Dividends paid—$0$0$0$0$0$0$0$0$0$0
Buybacks———————————
Stock-based pay$62M$52M$67M$66M$68M$64M$84M$82M$82M$76M$55M

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$820M$756M$439M$417M$521M$632M$697M$474M$341M$529M
Debt—$52M$52M$57M$62M$64M$50M$10M———
Equity—$1.2B$733M$432M$400M$541M$627M$699M$479M$335M$518M
Total assets—$1.6B$1.2B$749M$588M$700M$783M$783M$540M$385M$561M
Shares (diluted)175M170M166M164M162M160M157M147.20B126.58B122.60B115.86B

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin90.5%91.7%91.5%94.3%98.0%97.8%97.7%96.7%94.5%92.7%82.2%
Operating margin10.2%9.8%24.1%-10.1%-43.2%-35.2%-64.9%-72.7%-110.6%-234.1%-1574.1%
Net margin30.1%36.5%23.6%-8.4%-41.8%-34.7%-63.7%-69.4%-109.6%-231.7%-1565.9%
FCF margin6.8%9.8%16.4%2.3%-22.1%-26.2%-32.5%-44.9%-75.8%-175.0%-1211.2%
ROIC—6.5%25.8%-11.9%-38.2%-22.2%-33.5%-27.5%-40.8%-68.9%-41.6%
ROE—31.9%30.9%-14.2%-53.9%-31.0%-44.9%-33.7%-51.2%-86.3%-52.3%

Frequently asked questions

What is Acadia Pharmaceuticals’s annual revenue?

$1.1B in fiscal 2025 and $1.2B over the twelve months to September 30, 2026.

How much profit does Acadia Pharmaceuticals make?

Net income was $391M in fiscal 2025 (net margin 36.5%).

Is Acadia Pharmaceuticals’s revenue growing?

Yes: revenue rose 11.9% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.